New $1.2 Billion Startup Aims to Cut Military Dependence on Imported War Dogs

U.S. defense and public safety agencies face a looming supply chain crisis as they prepare to rely on a new domestic source for genetically engineered working dogs. Warhound, a startup that emerged from stealth mode on Thursday, has raised $200 million in funding to develop these specialized animals. The venture, valued at $1.2 billion, aims to reduce the military’s heavy dependence on foreign-bred canines, which currently constitute over 80% of the U.S. working dog population.

The financial backing for Warhound includes investments from prominent firms such as Sequoia, 8VC, and Corner Ventures. Notably, the round also includes In-Q-Tel, a venture firm supported by the CIA and other U.S. intelligence agencies. This mix of private capital and intelligence-linked investment signals a strategic push to secure a domestic pipeline for critical defense assets.

The core premise of the business is that the current supply of working dogs is shrinking and often fails to meet service standards. According to the company, less than half of imported dogs are fit for duty. Warhound intends to use the gene-editing technology of Colossal Biosciences to create a new type of dog with traits specifically suited for demanding missions, including bomb detection and search operations.

Ben Lamm of Colossal Biosciences and Palmer Luckey of Anduril conceived the project after meeting at a conference roughly a year ago. Lamm noted that many traditional working dogs fail training due to inherited health issues, such as poor eyesight, cancer risks, or hip dysplasia. By studying top-performing breeds like the Belgian Malinois and German Shepherd, the team has established a biobank of cell lines to edit genes for improved health, longevity, and sensory capabilities.

The operational model involves a distinct division of labor. Colossal provides the genetic engineering technology and licenses it to Warhound. Anduril, meanwhile, supplies the hardware and software necessary for mission execution. This includes protective gear such as vests and goggles equipped with data sensors. These devices are designed to provide handlers with real-time situational awareness, effectively extending the dog’s capabilities without altering its internal biology.

Lamm emphasized that the enhancements are additive to the animal, describing the Anduril gear as existing 'on top of the dog, not in the dog.' The goal is to make the animals safer and more effective, which in turn protects their human handlers. Although Luckey is a partner in the venture, he holds no equity; Colossal owns the stake and supports the business through technology licensing.

The production timeline is aggressive. The first batch of dogs is currently being cloned and incubated, with births expected in early 2027. The company aims to have these animals in service within two years. Viagen, another entity owned by Colossal, will handle the cloning process, leveraging technology that already boasts a high success rate in the conservation of endangered species.

While Warhound has not yet disclosed pricing, it plans to sell to the Department of Defense, military service groups, police forces, and first responders. The company has briefed numerous government bodies on the initiative. To address welfare concerns, Warhound is working under the guidance of the American Humane Society to certify its training programs and ensure retired dogs can enter reunification programs.

The American Humane Society stated that it is pleased to be involved in the process, citing its scientific and ethical approach to animal care. For the U.S. market, this development represents a shift from importing biological assets to engineering them domestically, potentially creating a new high-value niche in the defense technology sector.